title: Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making.
abstract: The combination of basal insulin and glucagon-like protein 1 receptor agonists (GLP-1 RAs) is a new intriguing therapeutic option for patients with type 2 diabetes. In our daily practice we abbreviate this therapeutic concept with the term BIT (basal insulin combined incretin mimetic therapy) in a certain analogy to BOT (basal insulin supported oral therapy). In most cases BIT is indeed an extension of BOT, if fasting, prandial or postprandial blood glucose values have not reached the target range. In our paper we discuss special features of combinations of short- or prandial-acting and long- or continuous-acting GLP-1 RAs like exenatide, lixisenatide and liraglutide with basal insulin in relation to different glycemic targets. Overall it seems appropriate to use a short-acting GLP-1 RA if, after the near normalization of fasting blood glucose with BOT, the prandial or postprandial values are elevated. A long-acting GLP-1 RA might well be given, if fasting blood glucose values are the problem. Based on pathophysiological findings, recent clinical studies and our experience with BIT and BOT as well as BOTplus we developed chart-supported algorithms for decision making, including features and conditions of patients. The development of these practical tools was guided by the need for a more individualized antidiabetic therapy and the availability of the new BIT principle.
authors.affiliation: St. Elisabeth-Krankenhaus Leipzig, Biedermannstrasse 84, Leipzig, D-04277, Germany.
authors.forename: Gerhard H
authors.initials: GH
authors.lastname: Scholz
authors.affiliation: Sanofi-Aventis Dt. GmbH, Berlin, Germany.
authors.forename: Holger
authors.initials: H
authors.lastname: Fleischmann
keywords: basal insulin; decision making; exenatide; glucagon-like protein 1 receptor agonist; individualized therapy; liraglutide; lixisenatide; type 2 diabetes mellitus